Mutant PNPLA3 I148M protein as pharmacological target for liver disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Potential conflict of interest: Nothing to report. See Article On Page 1111 Following identification of the I148M protein variant of patatin‐like phospholipase domain‐containing 3 (PNPLA3) as a dominant genetic determinant of hepatic fat content,1 robust evidence has accumulated that the mutant (I148M) variant protein is a major determinant of the full spectrum of nonalcoholic fatty liver disease,2 as well as of steatohepatitis of diverse etiologies and of the progression toward cirrhosis and liver cancer.3 However, the precise molecular mechanisms underlying these associations remain to be defined. Indeed, while the I148M variant is associated with loss of enzymatic activity,4 genetic deletion of PNPLA3 in knockout mice confers no obvious hepatic lipid phenotype, while predisposition to steatosis seems to depend upon the accumulation of PNPLA3 on the surface of lipid droplets in mice overexpressing the mutant protein.5 In this issue, BasuRay and colleagues examined the mechanism linking the I148M variant with hepatic fat accumulation in Pnpla3I148M knock‐in mice compared to wild‐type controls.6 Starting from their previous discoveries, the authors confirm that triglyceride synthesis, oxidation, and secretion are unaltered in high sucrose–fed Pnlpa3I148M knock‐in mice, despite the observation that these mice develop hepatic steatosis. These findings are consistent with a direct effect of the mutant 148M protein in the induction of lipid retention by altering triglyceride remodeling in the lipid droplet.7 Among the key findings are that accumulation of the mutant 148M protein precedes hepatic fat accumulation and is dependent on reduced ubiquitylation and impaired proteasomal degradation of I148M PNPLA3. The ligation of ubiquitin molecules to Lys (K) or Met (M) residues is a highly regulated process responsible for posttranslational regulation of protein activity, localization, and for targeting proteins for proteasomal degradation. In the present study, in vivo inhibition of proteasomal activity, but not macroautophagy, markedly delayed wild‐type PNPLA3 degradation during fasting, revealing that the protein undergoes polyubiquitylation. However, proteasome inhibition did not further increase the high baseline levels of PNPLA3 148M protein, which was also shown to be less ubiquitylated. This phenomenon was confirmed in mice overexpressing either human wild‐type or mutant (I148M) PNPLA3, which is an important control, because human PNPLA3 has a longer protein sequence and higher baseline hepatic expression than the mouse ortholog.9 Finally, mice carrying another artificial mutant form of PNPLA3 (S47A) that disrupts its catalytic domain displayed a phenotype similar to that observed in Pnpla3I148M knock‐in mice. This last finding suggests that it is the lack of enzymatic activity that determines PNPLA3 entrapment and its association with the lipid droplet surface, where it is likely less accessible to ubiquitin ligases. The next steps will be to find out how this loss of enzymatic activity impairs PNPLA3's trafficking across intracellular membrane compartments, to elucidate the mechanisms and sites of PNPLA3 ubiquitylation, and to determine how the mutant PNPLA3 148M functions to inhibit the activity of other lipases on the lipid droplet (mainly PNPLA2/adipose triglyceride lipase), allowing fat accumulation. In a broader context, human genetic studies also support the hypothesis that accumulation of mutant PNPLA3 148M protein is necessary to induce liver damage.10 Along these lines another naturally occurring PNPLA3 polymorphism, rs2294918 encoding the E434K protein variant, was recently linked to reduced hepatic PNPLA3 protein abundance.10 Whether the 434K residue is ubiquitylated and contributes to the decrease PNPLA3 protein levels is presently not known, although predictive algorithms suggest that this residue is a candidate site in human PNPLA3. In contrast with the more common PNPLA3 combined 148M‐434E risk variant, carriage of the 148M‐434K version of the protein, which is expressed at low levels, did not predispose to liver damage. However, in the context of preserved enzymatic activity, the 434K variant slightly reduced the protective impact of wild‐type 148I PNPLA3.10 Taken together, these data suggest that accumulation of the 148M, but not wild‐type, PNPLA3 protein drives hepatic fat accumulation and that it may be possible to mitigate the effects of the 148M mutant by preventing its accumulation. Furthermore, because of the association in patients with nonalcoholic fatty liver disease with the 148M variant, we demonstrated that PNPLA3 expression in hepatic stellate cells is increased in the liver of carriers of the mutation, which is important because stellate cells are involved in the regulation of fibrogenesis and carcinogenesis.11 Paralleling what happens in hepatocytes, overexpression of the mutant I148M PNPLA3 protein in stellate cells in vitro impaired the release of retinol and lipids that r
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K. V., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Hepatology · doi:10.1002/hep.27242 · Cited by 379 · cited 1×
“Indeed, while the I148M variant is associated with loss of enzymatic activity,((4)) genetic deletion of PNPLA3 in knockout mice confers no obvious hepatic lipid phenotype, while predisposition to steatosis seems to depend upon the accumulation of PNPLA3 on the surface of lipid droplets in mice overexpressing the mutan…”
BackgroundBasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302
PNPLA3 I148M polymorphism and progressive liver disease
Dongiovanni, P. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6969 · Cited by 252 · cited 1×
“Following identification of the I148M protein variant of patatin-like phospholipase domaincontaining 3 (PNPLA3) as a dominant genetic determinant of hepatic fat content,((1)) robust evidence has accumulated that the mutant (I148M) variant protein is a major determinant of the full spectrum of nonalcoholic fatty liver…”
BackgroundSelf-citation
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Self-citationUpdate on NAFLD genetics: From new variants to the clinic
Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393
Self-citationNAFLD in children: new genes, new diagnostic modalities and new drugs
Nobili, V., Alisi, A., Valenti, L., Miele, L., Feldstein, A. E., & Alkhouri, N. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0169-z · Cited by 309
Self-citationNonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Metadata
- Authors
- Valenti, L., & Dongiovanni, P.
- Venue
- Hepatology
- Published
- 2017-08-26
- Volume
- 66
- Issue
- 4
- Pages
- 1026-1028
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2623329744
- Cited by
- 33
- References
- 3
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutant PNPLA3 I148M protein as pharmacological target for liver disease. https://app.cochat.ai/papers/10.1002/hep.29298
- The paper
- Valenti, L., & Dongiovanni, P. (2017). Mutant PNPLA3 I148M protein as pharmacological target for liver disease. Hepatology. https://doi.org/10.1002/hep.29298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.